Centrifugal Therapeutic Plasma Exchange in Pediatric Patients: A Single-Center Case Series From Japan
Research article published in Journal of clinical apheresis (2026)
Abstract
Centrifugal therapeutic plasma exchange (cTPE) has been increasingly adopted worldwide; however, pediatric data remain limited, particularly in Japan. To evaluate the feasibility, procedural characteristics, and safety of pediatric cTPE in a single-center cohort. We retrospectively analyzed pediatric cTPE sessions performed between 2021 and 2025, assessing procedural characteristics, adverse events, and laboratory changes. Nineteen pediatric patients underwent cTPE. For procedural analyses, 84 non-extracorporeal membrane oxygenation (ECMO) sessions were included. Peripheral arterial-venous access was used in 76.2% of sessions and central venous access in 23.8%. Median exchange time was 95 min (interquartile range [IQR] 81-113), and median blood flow rate was 1.23 mL/kg/min (IQR 0.87-1.94). All planned sessions were completed (feasibility 100%). No hypotension requiring intervention or clinically significant bleeding occurred. Ionized calcium < 1.0 mmol/L requiring supplementation occurred in 3.6% of sessions. Allergic reactions occurred in 2.4% of sessions, both associated with fresh frozen plasma use. Median per-session reduction rates were 70.8% for IgG and 65.8% for fibrinogen (both p < 0.001). In an exploratory analysis of non-ECMO sessions, red blood cell priming was not associated with clinically meaningful differences in periprocedural laboratory changes after adjustment for patient size and blood flow rate. Pediatric cTPE was feasible and associated with infrequent adverse events while achieving substantial reductions in IgG and fibrinogen. These findings provide practical procedural data to inform pediatric cTPE implementation in clinical settings.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta serie de casos japonesa de un solo centro de 19 pacientes pediátricos (84 sesiones no-ECMO) encontró que el intercambio de plasma terapéutico por centrifugación era factible (100% de finalización de sesiones) y generalmente seguro, con eventos adversos poco frecuentes y reducciones sustanciales por sesión en IgG (70.8%) y fibrinógeno (65.8%). Este es un procedimiento de aféresis extracorpórea y no tiene conexión con sanguijuelas medicinales o el secretoma de la sanguijuela; el descriptor probablemente surgió a través de términos de indexación compartidos de sangre/coagulación (p. ej., fibrinógeno) en lugar de cualquier relevancia para la hirudoterapia. La advertencia honesta, y el punto más importante, es que ASH debería mantener bajas las expectativas aquí: esta es una pequeña serie de casos pediátricos retrospectiva sobre intercambio de plasma, no terapia con sanguijuelas, y no ofrece nada sobre la eficacia o seguridad de la hirudoterapia.
Citación
Centrifugal Therapeutic Plasma Exchange in Pediatric Patients: A Single-Center Case Series From Japan.
Omori et al. · Journal of clinical apheresis, 2026
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026